Lv5
1090 积分 2023-10-09 加入
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
6小时前
待确认
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1天前
待确认
Sibeprenlimab (Voyxact) for primary immunoglobulin A nephropathy
1天前
求助中
Iptacopan in IgA Nephropathy - Final 24-Month Data
1天前
已完结
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
3天前
已完结
Lecanemab in Early Alzheimer's Disease
3天前
已完结
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
7天前
已完结
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
7天前
已完结
Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension
9天前
已完结
Targeting CD38 in Antibody-Mediated Rejection
9天前
已完结
皖公网安备34019202002308
